Phase II study of weekly irinotecan plus cisplatin in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma

Onkologie

Volumn 34, Issue 7, 2011, Pages 378-381

  Jin, Shidai ^a   Wang, Tongshan ^a   Chen, Xiaofeng ^a   Xu, Bei ^a   Sun, Jing ^a   Guo, Renhua ^a   Shu, Yongqian ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Clinical trial; Extrapulmonary small cell carcinoma; Irinotecan

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; EXTRAPULMONARY SMALL CELL CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; SMALL CELL CARCINOMA; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79960200975     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000329609     Document Type: Article

References (23)

1. Van der Heijden HF, Heijdra YF: Extrapulmonary small cell carcinoma. South Med J 2005;98:345-349.
2. Duquid JB, Kennedy AM: Oat-cell tumors of mediastinal glands. J Pathol Bacteriol 1930;33:93-99.
3. Remick SC, Ruckdeschel JC: Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy and outcome. Med Pediatr Oncol 1992; 20:89-99.
4. Remick SC, Hafez GR, Carbone PP: Extrapulmonary small-cell carcinoma. A review of the literature with emphasis on therapy and outcome. Medicine (Baltimore) 1987;66:457-471. (Pubitemid 18008935)
5. Kim JH, Lee SH, Park J, Kim HY, Lee SI, Nam EM, Park JO, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K: Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol 2004;34:250-254. (Pubitemid 43102885)
6. Brenner B, Tang LH, Klimstra DS, Kelsen DP: Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004;22:2730-2739. (Pubitemid 41103762)
7. Sengoz M, Abacioglu U, Salepci T, Eren F, Yumuk F, Turhal S: Extra-pulmonary small cell carcinoma: multimodality treatment results. Tumori 2003; 89:274-277. (Pubitemid 37014118)
8. Lo Re G, Canzonieri V, Veronesi A, Dal Bo V, Barzan L, Zancanaro C, Trovo M: Extrapulmonary small cell carcinoma: a single-institution experience and review of the literature. Ann Oncol 1994; 5:909-913.
9. Van Der Gaast A, Verwey J, Prins E, Splinter TA: Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas. Cancer 1990;65:422-424.
10. Galanis E, Frytak S, Lloyd RV: Extrapulmonary small cell carcinoma. Cancer 1997;79:1729-1736. (Pubitemid 27176355)
11. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M: Antitumor activity of 7-ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47:5944-5947. (Pubitemid 18018734)
12. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N, Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91. (Pubitemid 34438898)
13. Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A: Randomized phase III trial comparing irinotecan/ cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease smallcell lung cancer. J Clin Oncol 2006;24:2038-2043. (Pubitemid 46622112)
14. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage smallcell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27:2530-2535.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981; 47:207-214. (Pubitemid 11167383)
16. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
17. Ibrahim NB, Briggs JC, Corbishley CM: Extrapulmonary oat cell carcinoma. Cancer 1984;54:1645-1661. (Pubitemid 14006229)
18. Shahab N: Extrapulmonary small cell carcinoma of the bladder. Semin Oncol 2007;34:15-21. (Pubitemid 46161757)
19. Walenkamp AM, Sonke GS, Sleijfer DT: Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev 2009;35:228-236.
20. Jackman DM, Johnson BE: Small cell lung cancer. Lancet 2005;366:1385-1396.
21. Fukuoka M, Masuda N: Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol 1994;34:S105-111. (Pubitemid 24264054)
22. Jingwei Jiang, Xiaohua Liang, Xinli Zhou, Lizhen Huang, Ruofan Huang, Zhaohui Chu, Qiong Zhan: A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/ platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010;5:867-873.
23. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 1998;16:1068-1074. (Pubitemid 28108742)